What is TAO Synergies Inc.'s market cap?

TAO Synergies Inc. (TAOX) has a market capitalization of $25.9M and trades on NASDAQ.

Who are TAO Synergies Inc.'s competitors?

TAO Synergies Inc.'s key competitors include Biogen, MicroStrategy, Prothena Corporation plc Ordinary Shares, and others. These companies compete in similar markets and product categories.

Who does TAO Synergies Inc. partner with?

TAO Synergies Inc.'s notable partners include BitGo, Yuma Validator, LLC, Stanford University, and others.

What subsidiaries does TAO Synergies Inc. have?

TAO Synergies Inc.'s subsidiaries include TAOX Florida Inc..

Where is TAO Synergies Inc. headquartered?

TAO Synergies Inc. is headquartered in United States of America and employs approximately 6 people. It has been publicly traded since 2020.

TAO Synergies Inc.

TAOX

TAO Synergies Inc. is a diversified company operating at the intersection of biopharmaceuticals and decentralized artificial intelligence.

Market cap

$25.85M+64.7%

Table of contents

Earnings

Q1 2026 report

May 13, 2026

Revenue$388.8K EPS-$0.46

Read the full report

Next report

Aug 7, 2026 (In 1 week)

Revenue estimate$388.8K

EPS estimate-$12.75

Competitors

By market cap

MicroStrategy$36.0B-68.5%

Biogen$29.5B+56.0%

Prothena Corporation plc$455.5M+23.2%

SPR

Spruce Biosciences, Inc. $115.6M—

TAO Synergies Inc.$25.9M+70.3%

PAS

Passage Bio, Inc.$14.8M-32.5%

CNS Pharmaceuticals$7.4M-83.4%

Alzamend Neuro, Inc.$5.1M-36.5%

By revenue growth

MicroStrategy+3.0%

Biogen+0.3%

By net margin

MicroStrategy1,663.11%-575pp

Biogen8.81%-6.5pp

Profile

TAO Synergies Inc. is a diversified company operating at the intersection of biopharmaceuticals and decentralized artificial intelligence. The company is developing a therapeutic platform based on Bryostatin-1 for Alzheimer’s disease and other neurodegenerative disorders while simultaneously executing a cryptocurrency treasury strategy focused on the Bittensor network. Its core value proposition lies in advancing clinical-stage medical research while leveraging digital asset staking to generate revenue and capital appreciation.

Competitive position

The company holds exclusive licenses for specific therapeutic applications of Bryostatin-1 while maintaining a specialized 'long-only' treasury position in the decentralized AI crypto sector.

GeographiesUnited States, Global

Customer segmentsPatients, Blockchain Networks, Institutional Investors

Business modelR&D, IP Licensing, Digital Asset Staking, Content Media

SuppliersNational Cancer Institute (NCI), Stanford University, Academic research institutions, Cryptocurrency exchanges, Blockchain protocol developers

CustomersClinical trial participants, Pharmaceutical manufacturers, Bittensor network participants, Digital asset custodians

CountryUnited States of America

Listed2020

Employees6.0

CEOJoshua N. Silverman

SectorHealthcare

IndustryBiotechnology

Websitesynaptogen.com

FilingsSEC EDGAR

Questions, answered.

What is TAO Synergies Inc.'s market cap?: TAO Synergies Inc. (TAOX) has a market capitalization of $25.9M and trades on NASDAQ.
Who are TAO Synergies Inc.'s competitors?: TAO Synergies Inc.'s key competitors include Biogen, MicroStrategy, Prothena Corporation plc Ordinary Shares, and others. These companies compete in similar markets and product categories.
Who does TAO Synergies Inc. partner with?: TAO Synergies Inc.'s notable partners include BitGo, Yuma Validator, LLC, Stanford University, and others.
What subsidiaries does TAO Synergies Inc. have?: TAO Synergies Inc.'s subsidiaries include TAOX Florida Inc..
Where is TAO Synergies Inc. headquartered?: TAO Synergies Inc. is headquartered in United States of America and employs approximately 6 people. It has been publicly traded since 2020.